Clinical trials: Neoplasms by Site, open to volunteers
Colorectal Cancer
Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization
The goal of this interventional study is to create and test a comprehensive and low burden text message program within existing Community Health Centers (CHC) electronic records system to encourage patients to complete at home…
- Trial name
- CoSMMO (NCT07569250)
- Testing
- Personalized Text Message, Screening Concerns Text Message, Message Framing Text Message
- Where
- 4 sites in United States
- Volunteers
- 7,220 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Non Small Cell Lung Cancer, Metastatic Lung Cancer
Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer
This phase I study aims to evaluate the safety and effectiveness of adaptive pulsed radiotherapy combined with immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint…
- Trial name
- PROMISE (NCT06622174)
- Testing
- Pulse radiotherapy
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Breast Cancer
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or…
- Trial name
- NCT07003074
- Testing
- TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab
- Where
- 25 sites in China
- Volunteers
- 642 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Rectal Adenocarcinoma
Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer
The PRELUDE Study: A Prospective Cohort Study Comparing Neoadjuvant Radiotherapy Followed by Total Mesorectal Excision Versus Upfront Surgery in Patients with Locally Advanced Proximal Rectal Cancer The PRELUDE Study is a…
- Trial name
- PRELUDE (NCT07802197)
- Testing
- radiotherapy, surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul University
Non-small Cell Lung Cancer
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally…
- Trial name
- TROPION-Lung14 (NCT06350097)
- Testing
- Osimertinib, Datopotamab Deruxtecan
- Where
- 167 sites in United States, Australia and 17 more
- Volunteers
- 582 people
- Sponsor
- AstraZeneca
Breast Cancer, Gynecologic Cancers
Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients
Participants recruited for this study will be breast cancer or gynecological cancer patients who agree to participate in an exercise study examining the effects of chemotherapy on muscle mitochondrial oxidative capacity, a…
- Conditions
- Breast Cancer, Gynecologic Cancers, Mitochondrial Function
- Trial name
- NCT06672497
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of South Carolina
Prostate Cancer
A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.
The purpose of this research is to test whether a new investigational Molecular Imaging (MI) agent called 61Cu-NU101 is equal to or better than a currently used MI agent, Pylarify, for the detection of prostate cancer metastases.
- Trial name
- NCT07635524
- Testing
- Cu-NU101
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC)
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer.
- Conditions
- Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer (Diagnosis)
- Trial name
- IKF-ReWoLuTe (NCT07510724)
- Where
- 2 sites in Austria, Germany
- Volunteers
- 240 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Ileostomy - Stoma, Colorectal Surgery
Readmission and Dehydration Prevention in Patients With Elective Ileostomy
The goal of this prospective observational study is to evaluate the adherence to DRIP score calculation and the application rate of each proposed item to prevent dehydration and readmission in patients undergoing ileostomy…
- Conditions
- Ileostomy - Stoma, Colorectal Surgery, Dehydration
- Trial name
- PREDESTO (NCT06824623)
- Where
- 7 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Multidisciplinary Italian Study group for STOmas (MISSTO)
Prostate Cancer
Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis
Prostate biopsy usually combines magnetic resonance imaging/ultrasound (MRI/US) cognitive fusion targeted biopsy with systematic biopsy.
- Trial name
- IBIS-PC (NCT07795723)
- Testing
- MRI/US Cognitive Fusion Targeted Biopsy Plus Ipsilateral Systematic Biopsy, MRI/US Cognitive Fusion Targeted Biopsy Plus Bilateral Systematic Biopsy
- Where
- China
- Volunteers
- 454 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Biliary Tract Cancer
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
The study was designed to evaluate the efficacy and safety of HRS-4642 monotherapy or in combination with adebrelimab in the treatment of advanced biliary tract tumor patients.
- Trial name
- NCT06620848
- Testing
- HRS-4642 monotherapy, HRS-4642 and adebrelimab combination therapy
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Shanghai Zhongshan Hospital
Bleeding After GI Endoscopy
Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Tumor Bleeding: A Randomized Controlled Trial
Background Gastrointestinal bleeding is a common disease among the population in Taiwan, with gastrointestinal tumor bleeding accounting for 3-5% of cases.
- Trial name
- NCT07540026
- Testing
- 3g of sucralfate powder and 1.5g of tranexamic acid powder, Standard Treatment
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Cheng-Kung University Hospital
Hematologic Malignancy, Solid Malignancy
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
- Trial name
- NCT06208878
- Testing
- Non Interventional
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- CRISPR Therapeutics AG
Hematologic Neoplasms, Influenza
Influenza Vaccination Strategy for Patients With Hematologic Malignancy
This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent…
- Conditions
- Hematologic Neoplasms, Influenza, Immunogenicity
- Trial name
- (HEM-FLU) (NCT07485855)
- Testing
- High-dose trivalent inactivated influenza vaccine (HD-IIV3), MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4), Standard-dose trivalent inactivated influenza vaccine (SD-IIV3)
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Asan Medical Center
Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.
- Trial name
- NCT06948448
- Testing
- ONO-4578, Opdivo®, Oxaliplatin
- Where
- 39 sites in United States, Canada and 4 more
- Volunteers
- 144 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Melanoma Stage IV, Solid Tumor
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy.
- Trial name
- NCT06425926
- Testing
- GIM-531, Anti-PD-1 monoclonal antibody
- Where
- 11 sites in United States
- Volunteers
- 117 people
- Sponsor
- Georgiamune Inc
Ovarian Cancer, Ovarian Carcinoma
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
This is a multicenter, open-label Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of sequentially administered CD146-targeted and GPC3-targeted CAR-T cell therapy in patients with advanced relapsed or…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovarian Sarcoma, Ovarian Cancer Stage IV
- Trial name
- BAH2573-104 (NCT07067255)
- Testing
- GPC3 CD146 CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Essen Biotech
Renal Cell Cancer
WIRE - Novel Treatments in Renal Cell Cancer
Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when different IMPs are given as monotherapy or as combination therapy.
- Trial name
- WIRE (NCT03741426)
- Testing
- Olaparib, Cediranib, Volrustomig
- Where
- 7 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- CCTU- Cancer Theme
Breast Cancer
Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy
Background Clinical N3 (cN3) breast cancer represents a high-risk subgroup of locally advanced disease. After neoadjuvant systemic therapy (NST), patients who achieve a clinical complete response (cCR) in initially involved but…
- Trial name
- NCT07829848
- Testing
- standard boost, boost omission
- Where
- China
- Volunteers
- 534 people
- Sponsor
- Fudan University
Metastatic Colorectal Carcinoma
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
The presence of a BRAFV600E mutation is a marker of poor prognosis in patients with mCRC and associated with a median overall survival (mOS) of approximately 12 to 14 months compared to 20 to 25 months for patients with BRAF…
- Trial name
- BERING-CRC (NCT04673955)
- Testing
- Encorafenib, Cetuximab
- Where
- 70 sites in Austria, Germany
- Volunteers
- 500 people
- Sponsor
- Pierre Fabre Pharma GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.